10-Q/A: Bio Essence Corp. Files Amended 10-Q/A Report for Q1 2024, Restating Financials and Addressing Internal Control Weaknesses

Bio Essence Corp. has filed an amended quarterly report on Form 10-Q/A for the period ended March 31, 2024, to update disclosures regarding internal controls and restate certain financial figures.

Summary

• Bio Essence Corp. filed an amendment to its Form 10-Q for the quarter ended March 31, 2024, to update disclosures regarding the company's internal controls.
• The amendment includes restatements of the consolidated balance sheet and statement of income for the three months ended March 31, 2024.
• The company had no revenues from continuing operations for the three months ended March 31, 2024 and 2023.
• The company reported a net income of $133,939 for the three months ended March 31, 2024, which includes a net gain of $256,925 from discontinued operations.
• The company's management concluded that its internal control over financial reporting was not effective as of March 31, 2024.
• The company plans to increase income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities.
• Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.
• The company's ability to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the restatement of financials, the identified weaknesses in internal controls, the lack of revenue from continuing operations, and the company's going concern risk. However, the successful sale of subsidiaries and the management's efforts to raise capital provide some positive aspects.

Positives

• The company reported a net income of $133,939 for the three months ended March 31, 2024, driven by gains from discontinued operations.
• The company successfully sold its subsidiaries BEP and BEH, generating cash inflows of $300,000 and $400,000, respectively.
• Management is actively pursuing strategies to improve sales, profitability, and secure additional funding.

Negatives

• The company's management concluded that its internal control over financial reporting was not effective as of March 31, 2024.
• The company had no revenues from continuing operations for the three months ended March 31, 2024 and 2023.
• The company has a working capital deficit of $2,021,158 as of March 31, 2024.
• The company's auditors have not conducted an audit of the company's controls and procedures regarding ICFR and therefore expresses no opinion with regards to the effectiveness or implementation of the company's controls and procedures with regards to ICFR.
• The company incurred net losses of $122,986 and $23,064 from the company's continuing operations for the three months ended March 31, 2024 and 2023, respectively.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenue and raise additional funds.
• The company's management has identified material weaknesses in its internal control over financial reporting.
• The company faces challenges in meeting upcoming cash requirements due to its working capital deficit and history of losses.
• The company's reliance on loans from a major shareholder presents a risk if this funding source becomes unavailable.
• The pandemic could result in significant disruption of global financial markets, reducing the company's ability to access capital, which could negatively affect the company's liquidity.

Future Outlook

The company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.

Management Comments

• Management intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.
• Management concluded that, as of March 31, 2024, our ICFR were not effective at the reasonable assurance level based on those criteria.
• The company's management believes it will need $1.2 million cash to continue its current business for the next 12 months.

Industry Context

The health supplement industry is competitive, and Bio Essence Corp.'s performance is affected by factors such as consumer demand, regulatory changes, and economic conditions. The company's shift towards discontinued operations and focus on raising capital suggests a strategic realignment in response to these industry dynamics.

Comparison to Industry Standards

• It is difficult to compare Bio Essence Corp. to industry standards due to the limited information provided and the company's specific circumstances.
• However, the company's lack of revenue from continuing operations and its reliance on discontinued operations for income are concerning and may indicate underperformance compared to peers.
• The identified weaknesses in internal control over financial reporting also raise concerns about the reliability of the company's financial information.
• Without more detailed information about the company's specific market segments, product offerings, and competitive landscape, it is challenging to provide a more comprehensive comparison to industry standards.

Related Party Transactions

• At March 31, 2024 and December 31, 2023, the Company had loans from one major shareholder (also the Company's senior officer) for $1,370,746 and $1,180,046, respectively.
• At March 31, 2024 and December 31, 2023, the Company had loan from another major shareholder for $608,631 for settling the litigation.
• On May 31, 2023, the Board of Directors of Bio Essence Corp. approved a debt-to-equity conversion whereby Ms. Yan receives 5,000,000 shares of the Company's common stock in exchange for retirement of the $2,500,000 debt.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity offerings.
• Employees may be affected by the company's efforts to improve efficiency and reduce costs.
• Customers may experience changes in product offerings or service levels as the company realigns its business strategy.
• Creditors face the risk of non-payment if the company is unable to improve its financial performance and liquidity.

Next Steps

• The company needs to strengthen its sales force and increase marketing and promotion activities to generate more revenue.
• The company needs to raise additional funds through a private or public offering, or by obtaining loans from banks or others.
• The company needs to address the identified weaknesses in its internal control over financial reporting.
• The company needs to improve its liquidity and working capital position.

Key Dates

Keywords

internal controls, financial reporting, going concern, discontinued operations, restatement, liquidity, capital resources, net income, net loss, Bio Essence Corp